Last reviewed · How we verify

Keymed Biosciences Co.Ltd — Portfolio Competitive Intelligence Brief

Keymed Biosciences Co.Ltd pipeline: 0 marketed, 0 filed, 3 Phase 3, 2 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 3 Phase 3 2 Phase 2 18 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Stapokibatrt Stapokibatrt phase 3 Other
CM326 CM326 phase 3 OX40 agonist monoclonal antibody OX40 (CD134) Oncology
CM310 CM310 phase 3 PD-L1 inhibitor PD-L1 Oncology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. GlaxoSmithKline · 3 shared drug classes
  2. Merck Sharp & Dohme LLC · 2 shared drug classes
  3. Celltrion · 2 shared drug classes
  4. Innovent Biologics (Suzhou) Co. Ltd. · 2 shared drug classes
  5. Jiangsu HengRui Medicine Co., Ltd. · 2 shared drug classes
  6. Mabwell (Shanghai) Bioscience Co., Ltd. · 2 shared drug classes
  7. 3D Medicines (Sichuan) Co., Ltd. · 2 shared drug classes
  8. Pfizer · 2 shared drug classes

Subscribe to ongoing alerts

Every new pipeline event for Keymed Biosciences Co.Ltd:

Cite this brief

Drug Landscape (2026). Keymed Biosciences Co.Ltd — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/keymed-biosciences-co-ltd. Accessed 2026-05-16.

Related